Results 131 to 140 of about 20,268 (224)

Sleep-disordered breathing in patients with heart failure with preserved left ventricular ejection fraction. [PDF]

Sleep Breath
Grimm C, Viniol C, Degerli M, Hildebrandt O, Kesper K, Koehler U, Grimm W, Parahuleva M.   +7 more
europepmc   +1 more source

Ultrasound in Women's Health: Mechanisms, Applications, and Emerging Opportunities

Advanced Materials, Volume 38, Issue 14, 6 March 2026.
As healthcare moves toward decentralization, ultrasound technologies are evolving from strictly imaging tools in clinical settings into versatile diagnostic and therapeutic platforms, with growing roles addressing women's health needs. This review highlights how ultrasound's underlying physical mechanisms can be harnessed to reduce disparities in women'
Sarah B. Ornellas, Bilal Kizilaslan, Aastha Shah, Jason F. Hou, Yoonsoo Shin, Alejandra Hernandez Moyers, Claudia Lozano, Canan Dagdeviren   +7 more
wiley   +1 more source

Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease

Advanced Materials, Volume 38, Issue 17, 20 March 2026.
RNA interference (RNAi) nanomedicine revolutionizes treatment regimens for ischemic heart diseases by enabling tailored, sequence‐anchored gene regulation. This review highlights the recent advances in nanotechnology‐driven RNAi therapeutics for myocardial ischemia and discusses the key design principles that govern efficient delivery, providing ...
Han Gao, Da Pan, Hélder A. Santos
wiley   +1 more source

Cardiac markers for risk stratification and prognosis in elderly patients with HFpEF. [PDF]

Front Med (Lausanne)
Abusedera O, Sherif J, Karar L, Arekat D.   +3 more
europepmc   +1 more source

F‐Box and Leucine‐Rich Repeat Protein 4 (FBXL4) Maintains Sarcomere Integrity and Cardiac Function by Enhancing K48‐Linked Ubiquitinated Degradation of Profilin‐1 (PFN1)

Advanced Science, Volume 13, Issue 17, 23 March 2026.
Schematic diagram depicting the proposed signaling mechanisms underlying the effects of FBXL4 in the setting of cardiac hypertrophy. Under hypertrophic stimulation, cardiomyocytes‐specific overexpression FBXL4 maintains sarcomere integrity and cardiac function by enhancing K48‐linked ubiquitinated degradation of PFN1 at the K70 site.
Xingda Li, Xueqi He, Xinyuan Hao, Yu Zhang, Xin Zhao, Shuang Wang, Zhenru Wang, Haonan Du, Hongda Li, Lian Yi, Zhimin Du, Weijie Du   +11 more
wiley   +1 more source

Battling Congestion in HFpEF

JACC: Asia, 2022
Alex Pui-Wai Lee, Yiting Fan
openaire   +1 more source

Ninjurin1 in cardiovascular and vascular biology: From molecular mechanisms to therapeutic opportunities

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
NINJ1 mediates PMR in cardiovascular cell death, releasing DAMPs that amplify vascular inflammation. Dual NINJ1 paradox: membrane‐bound form drives endothelial NF‐κB/CXCL‐8 inflammation while soluble form provides atheroprotection. Pericyte NINJ1 regulates the critical balance between angiogenic sprouting and vessel maturation in ischaemic tissues ...
Muhammad Mamunur Rashid Mahib
wiley   +1 more source

Pulmonary artery denervation improves left ventricular diastolic function in patients with isolated post-capillary pulmonary hypertension secondary to heart failure with preserved ejection fraction: a safety and proof-of-principle cohort study. [PDF]

AsiaIntervention
Jiang X, Zhang H, Zhang J, Gu Y, Xie D, Wang Z, Chen SL.   +6 more
europepmc   +1 more source

Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 2, March 2026.
SGLT2 inhibitor therapy was associated with a significantly lower risk of the composite outcome of all‐cause mortality or heart failure hospitalization at one year, as well as each component individually. ABSTRACT Background Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular (CV) outcomes in patients with heart failure (HF) and ...
Shaikh Muhammad Daniyal, Naveen Murad Khatoon, Anas Rasool, Isbah Gul, Sabula Tabish, Shireen Asifa, Ayan Khalid, Zunaira Aftab, Muhammad Burhan, Syeda Laiba Fahim, Habiba Tauqir Gondal, Muhammad Asfandyar Nadir, Syed Zaeem Ahmed, Danish Ali Ashraf, Somaiya Ahmed   +14 more
wiley   +1 more source

LKB1–AMPK Signaling Pathway in Cardiovascular and Other Diseases

MedComm, Volume 7, Issue 3, March 2026.
The LKB1–AMPK pathway has a central regulatory role in various diseases. Dysfunction of this pathway can lead to pathological processes in cardiovascular diseases (atrial fibrillation, myocardial infarction, myocardial hypertrophy, atherosclerosis), metabolic diseases (diabetes and kidney disease), neurodegenerative diseases (Alzheimer's disease ...
Zhuo Chen, Qin Yang, Guo‐Wei He
wiley   +1 more source